Methodology and sources
What the calculators do, where every number comes from, and what we leave out on purpose.
The calculation
- Concentration (mg/mL) = mg of peptide in the vial ÷ mL of diluent added.
- Volume per dose (mL) = dose in mg ÷ concentration.
- Units = volume in mL × 100, because U-100 insulin syringes hold 100 units per mL (1 unit = 0.01 mL).
- Doses per vial = mg in the vial ÷ dose, rounded down. Water never changes this number.
Warnings appear when a dose does not fit the chosen syringe (0.3 mL = 30 units, 0.5 mL = 50 units, 1 mL = 100 units), is under 2 units, falls between the printed marks (1-unit steps on 0.3 and 0.5 mL syringes, 2-unit steps on 1 mL syringes), is over 1 mL, or is larger than the vial. The math runs in your browser and is covered by automated tests.
Where doses come from
- FDA-approved drugs: the current US prescribing information (label).
- Drugs in trials: doses used in a published or registered human trial, named on the page. Trial doses are not recommendations.
- Everything else: if no label or human trial gives a dose, we say "no established human dose" and show none. We never list vendor or forum "protocols".
Regulatory status
Status reflects FDA approvals, the FDA's 503A compounding category lists (updated May 14, 2026), the July 2026 Pharmacy Compounding Advisory Committee votes and the October 30, 2026 HHS draft enforcement-discretion policy. These changed several times in 2026, so each page shows the date we last checked (2026-11-16). Being allowed for pharmacy compounding is not the same as FDA approval.
Independence
We do not sell peptides and do not link to or rank peptide sellers. If we show ads in the future, they will never influence content.
Corrections
Found an error or a newer source? Email hello@peptidemath.app.
Sources
- FDA 510(k) K212499: BD insulin syringes for U-100 insulin
- embecta (BD): Ultra-Fine insulin syringes, 0.3, 0.5 and 1 mL
- Pfizer (Hospira): Bacteriostatic Water for Injection, USP, prescribing information
- CDC MMWR 1982: Neonatal deaths associated with use of benzyl alcohol
- USP General Chapter <797> Pharmaceutical Compounding: Sterile Preparations
- FDA: 503A bulk drug substance categories (updated May 14, 2026, PDF)
- PharmExec: FDA advisory committee votes to loosen restrictions on peptides (Jul 2026)
- Federal Register 2026-22192: HHS draft enforcement discretion policy for 503A compounding of certain peptides (Oct 30, 2026)
- FDA: Dosing errors associated with compounded semaglutide
- FDA: Concerns with unapproved GLP-1 drugs used for weight loss
Last checked 2026-11-16. How we pick and check sources: methodology.